1CollinsTC, Daley J, HendersonWH, et al. Risk factors for pro - longed length of stay aftermajor elective surgery. Ann Surg 1999 ;230 (2) :251 -259.
2Khuri SF, Dalcy J, HendersonW, et al. TheDepartmentofVet - erans Affairs'NSQIP. The first nationa, 1 validated, outcOme -based, risk - adjusted, and peer - controlled program for themeasure -ment and enhancement of the quality of surgical care. Ann Surg 1998 ;228 (4) :491 -507.
3Khuri SF, Daley J, HendersonW, et al. Risk adjustment of the postoperativemortality rate for the comparative assessment of the quality of surgical care: Results of the National Veterans Affairs Surgical- Risk Group. JAm Coll Surg 1997;185(4) :315 -327.
4Daly JM, LiebermanMD, Goldfine J, et al. Enteralnutritionwith supplemental arginine, RNA, and omega -3 fatty acids in patients after operation: Immunologic, metabolic, and clinical outcome.
5Daly TM, Weintraub FN, Shou J, et al. Enteral nutrition during multimodality therapy in uppergastrointestinal cancerpatients. Ann Surg 1995 ;221(4) :327 - 338. Surgery 1992;112(1):56-67.
9McIntyre AS. Thompson DG,Bumham WR,et al. The effect of bata - adrenoreceptor agonists and antagonists on fructose absorption in man. Ailment pharmacol Ther 1993;7(3) :267 -271.
二级参考文献13
1顾天爵.生物化学[M].北京:北京医科大学中国协和医科大学联合出版社,1995..
2陈灏珠.实用内科学（第11版）[M].北京:人民卫生出版社,2001.1785.
3Dall E, Tosini P, Zavaroni I, et al. Comparison of the metabolic changes in rats with hypertension secondary to fructose feeding or renal artery stenosis [J]. Am J Hypertens,1995, 8(5):524-526.
4Masson S, Henriksen O, Stengaard A, et al. Hepatic metabolism during constant infusion of fructose, compatative studies with 31P-magnetic resonance spectroscopy in man and rats [J]. Biochim Biophys Acts, 1994, 1199(2):166-168.
5McIntyre AS, Thompson DG, Burnham WR, et al. The effect of beta-adrenoreceptor agonists and antagonists on fructose absorption in man [J]. Aliment Pharmacol Ther,1993, 7(3):267-271.
6Martines D, Martines V,Pasini M, et al. Carbohydrate-induced thermogenesis in liver cirrhosis: glucose vs. fructose. Nutrition,1994,10:521-526.
7Kruszynska YT, Harry DS, Fryer LG, et al. Lipid metabolism and substrate oxidation during intravenous fructose administration in cirrhosis. Metabolism, 1994,43:1171-1181.
8Mayes PA. Intermediary metabolism of fructose. Am J Clin Nutr, 1993,58(5 suppl):754-765.
9Coarse JF, Cardoni AA. Use of fructose in the treatment of acute alcoholic intoxication. Am J Hosp Pharm, 1975,32:518-519
5Collins TC,Daley J,Henderson WH,et al Risk factors for prolonged length of stay after major elective surgery[J].Ann Surg 1999,230(2):251-259.
6陈伟.果糖注射液-肝胆外科营养支持的最佳选择[N].医药经济报,2004年09月24日.
7顾天爵主编.生物化学[M].北京:人民卫生出版社,1995.196
8Merediz EF,Dyer J,Salmon KS,et al.Molecular characterization of fructosetransport in equine small intestine[J].Equine Vet J ,2004,36(6):532-538.
9BumsSP,Murphy HC,lies RA,et al.Hepatic intralobular mapping offruetose metabolism in the rat liver[J].Biochem J,2000,15(Pt2):539-545.
10Gabriely I,Shamoon H.Fructose normalizes specific counter regulatoryresponses to hypoglycemia in patients with type 1 drabetes[J].Diabetes,2005,54(3):609-616.
